Free Trial
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Mersana Therapeutics logo
$6.64 -0.20 (-2.86%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Key Stats

Today's Range
$6.55
$7.00
50-Day Range
$0.31
$10.18
52-Week Range
$6.47
$70.75
Volume
93,097 shs
Average Volume
166,073 shs
Market Capitalization
$826.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.00
Consensus Rating
Buy

Company Overview

Mersana Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

MRSN MarketRank™: 

Mersana Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 219th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mersana Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Mersana Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mersana Therapeutics is -11.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mersana Therapeutics is -11.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Mersana Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.59% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 23.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mersana Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mersana Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.59% of the float of Mersana Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mersana Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Mersana Therapeutics has recently decreased by 23.82%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mersana Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for MRSN on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mersana Therapeutics' insider trading history.
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Mersana Therapeutics Inc (MRSN) - Investing.com
See More Headlines

MRSN Stock Analysis - Frequently Asked Questions

Mersana Therapeutics' stock was trading at $35.75 at the beginning of the year. Since then, MRSN stock has decreased by 81.4% and is now trading at $6.6350.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings data on Thursday, May, 15th. The company reported ($4.75) earnings per share for the quarter, beating the consensus estimate of ($5.25) by $0.50. The firm earned $2.75 million during the quarter, compared to the consensus estimate of $6.05 million. Mersana Therapeutics had a negative net margin of 217.63% and a negative trailing twelve-month return on equity of 990.16%.
Read the conference call transcript
.

Mersana Therapeutics's stock reverse split on Friday, July 25th 2025.The 1-25 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/15/2025
Today
7/29/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRSN
CIK
1442836
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$250.00
Low Price Target
$75.00
Potential Upside/Downside
+1,855.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.19 million
Net Margins
-217.63%
Pretax Margin
-216.41%
Return on Equity
-990.16%
Return on Assets
-48.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.83
Quick Ratio
1.83

Sales & Book Value

Annual Sales
$40.50 million
Price / Sales
20.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.08) per share
Price / Book
-83.11

Miscellaneous

Outstanding Shares
124,630,000
Free Float
108,429,000
Market Cap
$828.66 million
Optionable
Optionable
Beta
0.79

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MRSN) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners